Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4197194 | 0.78 | SLC6A2 (0.42) | TAAR1BCHEAOC3HRH3MEN1 | |
| SCHEMBL1778321 | 0.70 | ALDH1A1 (0.44) | BCHEAOC3MEN1KMT2AALDH1A1 | |
| SCHEMBL9233468 | 0.69 | SLC6A2 (0.43) | TAAR1MEN1KMT2AALDH1A1SIGMAR1 | |
| SCHEMBL18107005 | 0.67 | AOC3 (0.42) | BCHEAOC3HRH3MEN1KMT2A | |
| SCHEMBL4197204 | 0.65 | SLC6A2 (0.38) | BCHEMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL30136331 | 0.64 | TAAR1 (0.58) | TAAR1AOC3HRH3KMT2AALDH1A1 | |
| SCHEMBL8062343 | 0.64 | TAAR1 (0.58) | TAAR1AOC3HRH3KMT2AALDH1A1 | |
| SCHEMBL11555598 | 0.63 | TAAR1 (0.49) | TAAR1AOC3HRH3MEN1KMT2A | |
| SCHEMBL4817308 | 0.63 | SLC18A2 (0.62) | HRH3SIGMAR1 | |
| SCHEMBL30520870 | 0.62 | TAAR1 (0.61) | TAAR1AOC3HRH3KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192173-A1 | ANTI-TUBERCULAR DRUGS: COMPOSITIONS AND METHODS | SEQUELLA, INC. | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192173-A1 | ANTI-TUBERCULAR DRUGS: COMPOSITIONS AND METHODS | RIF1, TERT, ELL | TAAR1 2139/4885BCHE 442/4885AOC3 3432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.